CBDCA + Pemetrexed + Bevacizumab and Its Maintenance Chemotherapy in a Case of Solitary Breast Metastasis from a Lung Adenocarcinoma Resistant to Gefitinib

CBDCA + Pemetrexed + Bevacizumab and Its Maintenance Chemotherapy in a Case of Solitary Breast Metastasis from a Lung Adenocarcinoma Resistant to Gefitinib

Based on the AVAPERL trial (36th ESMO 2011), CBDCA + pemetrexed + bevacizumab and its maintenance chemotherapy with pemetrexed + bevacizumab is a new promising regimen for the treatment of advanced non-small-cell lung adenocarcinoma. Herein, we report the rare case of a patient with solitary breast...

Full description

Bibliographic Details
Main Authors: Kazuhide Sato, Yoshihiro Takeyama, Motoi Yoshihara, Toshio Kato, Hiroyuki Hashimoto, Yasutaka Fukui, Hideo Gonda, Ryujiro Suzuki
Format: Article
Language:English
Published: Karger Publishers 2012-10-01
Series:Case Reports in Oncology
Subjects:
Solitary breast metastasis
Non-small-cell lung carcinoma
T790M
CBDCA + pemetrexed + bevacizumab
Maintenance therapy
Tyrosine kinase inhibitor resistance
Online Access:http://www.karger.com/Article/FullText/343678

Internet

http://www.karger.com/Article/FullText/343678

Similar Items